Preventing Hospitalizations Due to Adverse Vaccine Responses
Thermophobic Imidazoquinoline-Based TLR-7/8 Agonist Polymer Conjugates as Vaccine Adjuvants
Preventing Hospitalizations Due to Adverse Vaccine Responses
Thermophobic Imidazoquinoline-Based TLR-7/8 Agonist Polymer Conjugates as Vaccine Adjuvants
Department of Chemistry and Biochemistry, Miami University
Sarah A. Lebish*, Muhammad Haroon, Ph.D., Nyan Stephen, Pranto S.M. Al Muied, Seyedeh Asma Najibi, Ph.D., Amy E. Nielsen, Ph.D., and Rock J. Mancini, Ph.D.
(*Undergraduate Presenter)
Our research is interested in the development of a thermophobic adjuvant that modulates activity in response to increases in temperature to improve vaccine efficacy and safety. By conjugating a TLR-7/8 agonist to thermoresponsive pNIPAM, we hypothesize that immune response to be temperature controlled to prevent hospitalizations caused by severe adverse vaccine reactions.
Undergraduate Presenter
Sarah Lebish
Atlanta, GA
Biochemistry, Pre-Med